Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-021700
Filing Date
2025-02-14
Accepted
2025-02-14 20:25:23
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5286
  Complete submission text file 0000950170-25-021700.txt   7039
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Subject) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-81034 | Film No.: 25632152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 8586776077
FORWARD VENTURES V LP (Filed by) CIK: 0001232643 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13G